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Haoran Zhang, Junmin Chen, Wenzhong QueUmbilical cord blood has emerged as an alternative stem cell source to bone marrow or peripheral blood
stem cells. Umbilical cord blood transplantation (UCBT) is also potentially curative for acute leukemia.
However, the effect of unrelated donor bone marrow transplantation (UBMT) and UCBTon the outcome
of patients with acute leukemia has not been systematically reviewed. In the present meta-analysis, we sys-
tematically searched Cochrane Library, MEDLINE, EMBASE, and CNKI up to May 2011. Two reviewers ex-
tracted data independently. Seven studies totaling 3389 patients have been assessed. Pooled results found
that the incidence of engraftment failure and transplantation-related mortality were higher in UCBT than
in UBMT, and relative risks (RRs) were 4.27 (95% confidence interval [CI], 2.94-6.21) and 1.27 (95% CI,
1.01-1.59), respectively. The rates of acute and chronic graft-versus-host disease (GVHD) in the UCBT group
were significantly lower than that in the UBMT group, and RRs were 0.71 (95% CI, 0.65-0.79) and 0.69 (95%
CI, 0.52-0.91), respectively. The relapse rate was similar between the UCBTand UBMT group. The leukemia-
free survival (LFS) and overall survival (OS) were significantly lower in the UCBT group than in the UBMT
group; RRs were 1.14 (95% CI, 1.07-1.22) and hazard ratios (HRs) were 1.31 (95% CI, 1.16-1.48), respec-
tively. Subgroup analysis showed that in patients with acute lymphoblastic leukemia (ALL), the survival
was similar between UCBTand UBMT.
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Meta-analysisINTRODUCTION
Bone marrow transplantation (BMT) is a widely
accepted treatment for many hematologic malignan-
cies, including leukemia, lymphoma, and multiple
myeloma. Current bone marrow (BM) from HLA-
matched unrelated donors has been a major alternative
graft source [1,2]. However, many patients are unable
to proceed to an allogeneic transplantation because
of the lack of a suitable BM donor. In recent years,
umbilical donor cord blood (UCB) has emerged
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plantation in patients who lack HLA-matched marrow
donors. The first successful umbilical donor cord
blood transplantation (UCBT) was performed in
1988 in a child with Fanconi anemia who underwent
UCBT from his HLA-identical newborn sister [3].
Since that time, more than 20,000 UCBTs have been
performed throughout the world [4-7]. The advent
of UCBT has significantly improved allogeneic
transplantation as a treatment option by expanding
the available donor pool.
This increase has been stimulated by the recogni-
tion that UCBT has certain advantages relative to un-
related donor bone marrow transplantation (UBMT),
including rapid availability, low risk of infection trans-
mission, absence of donor risk, and the relatively lower
risk of graft-versus-host disease (GVHD). At the same
time, the disadvantages of UCBT are the limited cell
dose, delayed engraftment, and lack of additional im-
mune cells if donor lymphocytes are needed [8].
Thus, large variation in practice and considerable un-
certainty exists with respect to the relative effects of
UCBT versus UBMT on the outcomes of patients
with acute leukemia. However, differences in the
Biol Blood Marrow Transplant 18:1164-1173, 2012 1165UCBT versus UBMTpatient populations and transplantation protocols may
have also contributed. In order to address this ques-
tion, several comparative clinical studies [9-15] have
been conducted to evaluate the benefit of UCBT for
acute leukemia compared with UBMT.
However, the effect of UCBT and UBMT on the
outcome of patients with acute leukemia has not
been systematically reviewed. Herein, we report the
differences in the outcomes between UCBT and
UBMT as therapy for acute leukemia. This analysis
anticipated that results for patients with acute leuke-
mia might differ from those for patients with other dis-
eases. The main objective of this systematic literature
review was to evaluate whether UCBT is equivalent
to UBMT in treating patients with acute leukemia.METHODS
This reviewwasperformedaccording to the standard
described in the ‘‘Preferred reporting items for system-
atic reviews and meta-analyses’’ statement [16].Selection Criteria
All comparative studies of UCBT versus UBMT
were selected whether or not randomization was
used. Patients were children and adults requiring allo-
geneic hematopoietic stem cells transplantation to
treat acute leukemia. Data for engraftment failure,
GVHD, transplantation-related mortality (TRM), re-
lapse, and survival had to be available. Each study was
critically appraised for validity based on consistency,
accuracy, and balance between treatment groups.
Studies without comparable patient demographics be-
tween the 2 comparative groups were excluded. The
studies with case reports, poor quality, and little infor-
mation were excluded. There were far more review ar-
ticles than primary studies on cord blood
transplantation (CBT), and all review articles reiterat-
ing previous data were excluded.Search Strategy
The following expanded Medical Subject Head-
ings (MeSH) terms were used for the initial literature
search: ‘‘cord blood,’’ ‘‘bone marrow,’’ ‘‘transplant,’’
‘‘transplantation,’’ and ‘‘transplants.’’ The electronic
databases searched were: MEDLINE (1966 to May
2011), EMBASE (1980 to 2011 week 20), Cochrane
Library (issue 2, 2011), and Chinese National Knowl-
edge Infrastructure (CNKI; 1994 to May 2011). No
language or date restrictions were applied. Reference
lists of all included studies and reviews related to the
topic of the present meta-analysis were manually
searched for other potentially eligible studies. Full
text articles were obtained to extract the data for this
analysis.Methods of the Review
Potential studies for inclusion were identified from
the search results. Two reviewers (H.Z. andW.Q.) in-
dependently applied the search strategy to selected ref-
erences from databases. The titles and abstracts of the
articles were reviewed independently. When there
was a doubt, the full article was retrieved for further
scrutiny. The 2 authors independently assessed each
full study report to see whether it met the review’s in-
clusion criteria, and authors were contacted for more
information and clarification of data as necessary. Dis-
agreements on inclusion of studies were resolved by the
senior reviewer (J.C.) until consensus was obtained.
The authors of individual studies were contacted di-
rectly to provide further information when necessary.
We systematically reviewed all data on comparative
studies of UCBT versus UBMT in which survival was
the key outcome measure. Unrelated donor searches
were eligible for analysis of graft availability and out-
come. To obtain reliable evidence on the relative effect
of UCBT versus UBMT in the primary treatment of
adults and children with acute leukemia, results from
independent and comparable studies were integrated
to increase statistical power. The primary outcomes
were estimated survival; secondary outcomes studied
included engraftment, GVHD, TRM, and relapse.
Statistical Analysis
Dichotomous data for each arm in a particular
study were expressed as proportions or risks, and the
treatment effect as relative risks (RRs), with their re-
spective 95% confidence intervals (CIs). Hazard ratios
(HRs) were the preferred form of data for calculating
overall survival (OS). Heterogeneity was explored by
the chi-squared test with a significance set at a P value
of .10, and the quantity of heterogeneity was measured
by I2 [17]. When significant heterogeneity was found
with the fixed-effects model, a random-effects model
was used to estimate the overall treatment effect.
Forest plots were used to summarize the results of
included studies, and inverted funnel plots and the
Egger’s test were used to examine publication bias.
All analyses were done in Review Manager (version
5.1.2; The Cochrane Collaboration, Oxford, England)
and STATA software package (version 11.0; Stata-
Corp LP, College Station, TX).RESULTS
Description of Studies
Bibliographic searches from the Cochrane Li-
brary, MEDLINE, EMBASE, and CNKI databases
yielded 387 articles, of which 359 were excluded.
The rest of the records were assessed, and a further
21 were excluded for various reasons according to
the inclusion and exclusion criteria (Figure 1). Finally,
Figure 1. Flow chart of included and excluded studies.
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(Table 1). Four studies were performed on pediatric
patients and 3 studies were on adults. These studies
on children involved a total of 649 patients receivingTable 1. Characteristics of Included Studies
Studies Publication Year Study Population Stu
Rocha et al. [9] 2001 Children with acute leukemia U
U
Eapen et al. [10] 2007 Children with acute leukemia U
U
Rocha et al. [11] 2004 Adults with acute leukemia U
U
Jacobsohn et al. [12] 2004 Children with ALL U
U
Atsuta et al. [13] 2009 Adults with AML U
U
Atsuta et al. [13] 2009 Adults with ALL U
U
Smith et al. [14] 2009 Children with ALL U
U
Eapen et al. [15] 2010 Adults with acute leukemia U
U
UCBT indicates umbilical cord blood transplantation; UBMT, unrelated donor
acute myelogenous leukemia.UCBT and 601 patients receiving UBMT. A total of
550 undergoing UCBT and 1589 UBMT adult pa-
tients were included.
The majority of included studies were studies
with between 49 and 785 participants. However,
non-randomized and non-blinded comparative studies
were selected for this meta-analysis. We verified that
the patients included in 7 studies came from com-
pletely separate, not overlapping cohorts. The cohort
in the Eapen et al. [10] study included both CBT and
BMT from unrelated donors. Although no language
restrictions were imposed initially, for the full-text re-
view and final analysis, our resources only permitted
the review of articles published in the English lan-
guage.
Effects of Interventions
Engraftment failure
Five studies [9-12,14] reported the rate of
engraftment failure and these included 1635 patientsdy Arm
Number of
Patients
Median Age
Years (Range) HLA Matching
CBT 99 6 (2.5-10) 8% 6/6 HLA-matched
43% 1 antigen-mismatched
41% 2 antigen-mismatched
8% >3 antigen-mismatched
BMT 262 8 (5-12) 80.5% 6/6 HLA-matched
17.6% 1 antigen-mismatched
0.4% 2 antigen-mismatched
CBT 503 Not available 7% 6/6 HLA-matched
40% 1 antigen-mismatched
53% 2 antigen-mismatched
BMT 282 Not available 41% 6/6 HLA-matched
59% antigen-mismatched
CBT 98 24.5 (15-55) 6% 6/6 HLA-matched
51% 1 antigen-mismatched
39% 2 antigen-mismatched
4% 3 antigen-mismatched
BMT 584 32 (15-59) 100% 6/6 HLA-matched
CBT 26 3.9 (0.3-11.9) 15.4% 6/6 HLA-matched
38.5% 1 antigen-mismatched
42.3% 2 antigen-mismatched
3.8% 3 antigen-mismatched
BMT 23 2.5 (0.3-15.4) 87% 6/6 HLA-matched
13% 1 antigen-mismatched
CBT 173 38 (16-69) 7% 6/6 HLA-matched
20% 1 antigen-mismatched
73% 2 antigen-mismatched
BMT 311 38 (16-60) 100% 6/6 HLA-matched
CBT 114 34 (16-58) 7% 6/6 HLA-matched
22% 1 antigen-mismatched
71% 2 antigen-mismatched
BMT 222 32 (16-59) 100% 6/6 HLA-matched
CBT 21 7.0 (2.1-17.9) 9.5% 6/6 HLA-matched
52.4% 1 antigen-mismatched
38.1% 2 antigen-mismatched
BMT 34 7.0 (0.9-17.7) 100% 6/6 HLA-matched
CBT 165 Not available 6% 6/6 HLA-matched
24% 1 antigen-mismatched
70% 2 antigen-mismatched
BMT 472 Not available 100% 6/6 HLA-matched
bone marrow transplantation; ALL, acute lymphoblastic leukemia; AML,
Figure 2. Meta-analysis of the rates of engraftment failure for umbilical cord blood transplantation (UCBT) and unrelated donor bone marrow trans-
plantation (UBMT). M-H, Mantel-Haenszel; CI, confidence interval; df, degrees of freedom.
Biol Blood Marrow Transplant 18:1164-1173, 2012 1167UCBT versus UBMT(Figure 2). The result of the heterogeneity test in 2
groups showed P 5 .18 and I2 5 37%, indicating no
evidence of heterogeneity in the 5 studies; hence, the
fixed effect model was used. The rate of engraftment
failure in the UCBT group was significantly higher
than in the UBMT group (RR 5 4.27; 95% CI 5
2.94-6.21; P\ .00001).
Acute and chronic GVHD
All 7 studies reported the occurrence of GVHD.
The rates of acute GVHD (aGVHD) and chronic
GVHD (cGVHD) in the UCBT group were signifi-
cantly lower than those in the UBMT group (RR 5
0.71; 95% CI 5 0.65-0.79; P\ .00001 versus RR 5
0.69; 95% CI 5 0.52-0.91; P 5 .009, respectively;
Figure 3, Figure 4).
Relapse
All 7 studies reported the relapse rate after trans-
plantation, and the result is shown in Figure 5. The
rate of relapse in the UCBT group was similar to
that in the UBMT group (RR 5 0.98; 95% CI 5
0.77-1.24; P 5 .87).
Non-relapse mortality
All 7 studies reported the TRM, and the result is
shown in Figure 6. The TRM in the UCBT group
was significantly higher than that in the UBMT group
(RR 5 1.27; 95% CI 5 1.01-1.59; P 5 .04).
Leukemia-free survival
All 7 studies reported the leukemia-free survival
(LFS) between the 2 groups, and the result is shownin Figure 7. There was a significant difference in
LFS when studies were pooled. The LFS was lower
in UCBT compared with UBMT (RR 5 1.14; 95%
CI 5 1.07-1.22; P\ .0001).
Overall survival
Four studies [9,11-13] reported the OS between
the 2 groups, and the result is shown in Figure 8. There
was a significant difference in OS when studies were
pooled. The OS in the UCBT group was significantly
lower than that in the UBMT group (HR5 1.31; 95%
CI 5 1.16-1.48; P 5 .000).Subgroup Analyses
Children and adults
The rate of TRM and LFS in pediatric patients in
the UCBT group were non-significantly different
from that in the UBMT group (RR5 1.51; 95% CI5
0.98-2.34 and RR 5 1.10; 95% CI 5 0.99-1.22, re-
spectively). This meta-analysis showed that in adults,
the TRM was similar between UCBT and UBMT
(RR 5 1.13; 95% CI 5 0.99-1.29).
Acute lymphoblastic leukemia (ALL)
The rate of engraftment failure, cGVHD, and
TRM in the UCBT group were non-significantly dif-
ferent from that in the UBMT group (RR5 1.57; 95%
CI5 0.34-7.26 versus RR5 0.84; 95%CI5 0.61-1.17
versus RR 5 0.85; 95% CI 5 0.65-1.12, respectively).
The LFS and OS in the UCBT group were also non-
significantly different from that in the UBMT group
Figure 3. Meta-analysis of incidence of acute graft-versus-host disease (aGVHD) for umbilical cord blood transplantation (UCBT) and unrelated donor
bone marrow transplantation (UBMT). M-H, Mantel-Haenszel; CI, confidence interval; df, degrees of freedom.
1168 Biol Blood Marrow Transplant 18:1164-1173, 2012H. Zhang et al.(RR 5 1.07; 95% CI 5 0.89-1.29 versus HR 5 1.18;
95% CI 5 0.89-1.57, respectively).
Publication bias
Funnel plots and the Egger’s test were performed
to access the publication bias in studies. The shape of
the funnel plot (Figure 9) revealed obviously symmet-
rical distribution, which means no publication bias.
The Egger’s test did not suggest any evidence of pub-
lication bias (Egger’s regression test P values . .10).DISCUSSION
We performed a systematic review and meta-
analysis of clinical studies comparing UCBT to
UBMT in patients with acute leukemia. The results
showed that UCBT was associated with less GVHD,
more engraftment failure and TRM, similar relapse,
and shorter survival. There was no difference in LFS
and OS in patients with acute lymphoblastic leukemia
(ALL) when studies were pooled.
We applied a systematic methodology in which
studies were searched, selected, and analyzed, but be-
cause allocation to a particular treatment group was
based on the availability of suitable unrelated BM or
CB donors, randomized and blinded controlled studies
were not available. So, the studies are not randomized
controlled studies.
It is true that patients’ baseline characteristics were
similar in these studies, and the lack of availability of
fully matched unrelated donors often predicated theneed for less well-matched CB grafts. In addition,
the degree of match is less stringent for UCBT [18].
There were, however, explicit statements of intent, as
evident in the studies of Rocha et al. [11], Atsuta
et al. [13], Smith et al. [14], and Eapen et al. [15],
that patients were eligible for UCBT if fully matched
siblings or fully matched unrelated BM donors were
not available immediately or within a satisfactory
time frame. Therefore, we cannot fully exclude the
possibility of center biases in the treatment and selec-
tion of patients for UCBT or UBMT.
These studies demonstrated significant differences
in graft failure between UCBT and UBMT recipients.
The higher risk of graft failure may be related to sev-
eral factors, including immaturity of stem cells (which
might need more cell divisions before differentiation
to marrow progenitors), the lack of subpopulations
to facilitate engraftment [19], and the lower nucleated
cell and CD341 cell doses with the UCB grafts as
compared with the marrow allografts [20].
One study described a threshold of 1.7  105
CD341 cells/kg and suggested that cord blood units
containing less than this CD341 cell dose should be
considered deficient [7]. So, the main problem with
using UCB for transplantation is the relatively low
number of hematopoietic progenitor cells and hema-
topoietic stem cells in UCB compared with bone mar-
row or mobilized peripheral blood grafts, which
translates into increased risk of graft failure, delayed
hematopoietic engraftment [10,21], and delayed
immune reconstitution [22,23].
Figure 4. Meta-analysis of incidence of chronic graft-versus-host disease (cGVHD) for umbilical cord blood transplantation (UCBT) and unrelated
donor bone marrow transplantation (UBMT). M-H, Mantel-Haenszel; CI, confidence interval; df, degrees of freedom.
Biol Blood Marrow Transplant 18:1164-1173, 2012 1169UCBT versus UBMTThis meta-analysis was undertaken to determine
whether there is a relationship between stem cell
source and the development of acute and chronic
GVHD after allogeneic transplantation. This meta-
analysis showed that the rate of acute and chronicFigure 5. Meta-analysis of relapse rate after transplantation for umbilical c
transplantation (UBMT). M-H, Mantel-Haenszel; CI, confidence interval; df, deGVHD were higher in UBMT than in UCBT. The
incidence of GVHD among UCBT recipients has
been lower than recipients of matched UBMT,
because the UCB stem cells are immunologically na€ıve
[24-26], with low T cell–mediated cytotoxic capacityord blood transplantation (UCBT) and unrelated donor bone marrow
grees of freedom.
Figure 6. Meta-analysis of the rates of non-relapsemortality for umbilical cord blood transplantation (UCBT) and unrelated donor bonemarrow trans-
plantation (UBMT). M-H, Mantel-Haenszel; CI, confidence interval; df, degrees of freedom.
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geneic stimuli in the secondary mixed lymphocyte re-
action [27,28]. Lu et al. [29] recently demonstrated
a marked increased in CD161CD56– natural killer
cells in the peripheral blood after UCBT. The de-
creased incidence of GVHD with UCBT despite
HLA mismatch may be attributable in part to the im-
maturity and lower number of immunocompetent
donor T cells [18]. Although most patients were mis-
matched with their cord blood donors at 1 to 3 HLA
loci, the incidence of either grades II to IV aGVHD
or cGVHD was low and compares favorably with
that reported in several studies on UBMT. But, the
cGVHD in UCBT in the patients with ALL group
was non-significantly different from that in the
UBMT group.
These studies demonstrated no significant differ-
ences in relapse betweenUCBT andUBMT recipients.
Becauseof thedecreased incidenceofGVHDinpatients
undergoingUCBTand the delayedT cell recovery, one
concern has been the potential for a decreased graft-
versus-leukemia effect. However, studies have not dem-
onstrated an increased risk of relapse after UCBT [30].
Concerns raised about the possibility of an increased
risk of leukemia recurrence in UCBT recipients are de-
rived from the incidence and severity of both aGVHD
and cGVHD, which seemed to be less, and immaturity
and delayed engraftment, which impair the immune-
mediated antimalignancy effect afterUCBT.The prob-
ability of relapse after CBT was similar to that in the
BMT group, but suggested that the donor-derivedgraft-versus-tumor effect might be preserved [31,32].
Further optimization of cord selection, ex vivo
expansion, and biologic manipulation of UCB and the
immune system should help to decrease the risk of
recurrent leukemia [33].
Thismeta-analysis demonstrated significant differ-
ences in TRM between UCBT and UBMT recipients.
TRM remains as the main obstacle for successful
UCBT.The disadvantage of a higher TRMwill gener-
ate an adverse effect on survival. Compared with
patients transplanted from matched unrelated BM do-
nors, those given CBT from an unrelated donor expe-
rience a lower incidence ofGVHDand, due to a higher
risk of severe infectious complications [34,35], may be
exposed to an increased risk of TRM.
A major limitation to the use of UCB is the avail-
ability of sufficient numbers of hematopoietic progen-
itor cells for hemopoietic recovery [9-11,13,21,36,37].
There are significant differences in failure to engraft
between adults and children. The rate of adults and
children engraftment failure in the UCBT group
was significantly higher than in the UBMT group,
although shortening the period of neutropenia might
lead to lower early mortality [38]. Maybe one relevant
factor influencing the risk of TRM is the rate of en-
graftment failure.
Our analyses demonstrated significant differences
in survival between UCBT and UBMT recipients.
The advantage of a lower GVHD rate without any ap-
parent increase in relapse in UCBT transplantation
will offset any adverse effect of reduced cell dose on
Figure 7. Meta-analysis of leukemia-free survival for umbilical cord blood transplantation (UCBT) and unrelated donor bone marrow transplantation
(UBMT). M-H, Mantel-Haenszel; CI, confidence interval; df, degrees of freedom.
Biol Blood Marrow Transplant 18:1164-1173, 2012 1171UCBT versus UBMTsurvival. When UCBT was administrated in patients
with acute leukemia, impaired survival was observed
in this meta-analysis. The LFS and OS in the UCBT
group were significantly lower than that those in the
UBMT group. However, there was no difference inFigure 8. Meta-analysis of overall survival for umbilical cord blood transplanta
M-H, Mantel-Haenszel; CI, confidence interval.LFS and OS in patients with ALL when studies were
pooled. Although it is true that the analysis did show
that some of the confidence intervals are wide, and
the possibility of large differences has not been ex-
cluded, some studies thus far suggest that UBMT intion (UCBT) and unrelated donor bonemarrow transplantation (UBMT).
Figure 9. Funnel plot of the 7 studies. P5.401 for the Egger’s test. Each
point represents an individual study for the indicated association.
1172 Biol Blood Marrow Transplant 18:1164-1173, 2012H. Zhang et al.patients with ALL can result in long-term survival in
many patients. The results thus far suggest that
UCBT can result in long-term LFS and OS in patients
with ALL. Some studies have reported OS in the range
of 49% to 65%, which is similar to UBMTs.
Results of the current study are consistent with
those of 3 previous meta-analyses. Two previously
publishedmeta-analyses includedpatientswithhemato-
logical diseases or hematological malignancies [39,40].
Another meta-analysis, published by Xu et al. [41]
(including 1453 patients in 7 studies), was limited to
children with hematological diseases or hematological
malignancies. However, in our meta-analysis, we only
analyzed clinical studies that only included adult and pe-
diatric patients with acute leukemia. To our knowledge,
this is the first meta-analysis that focused on this com-
parison in patients with acute leukemia. At the same
time, our review was performed according to the stan-
dard described in the ‘‘Preferred reporting items for sys-
tematic reviews and meta-analyses’’ statement [16].
Since that time, additional clinical studies determining
the effects of UCBT have also been reported. At the
same time, we should address the concern that the re-
sults withCBTcompared toBMTcould have improved
over time.
Our analysis does have several limitations. First,
the studies are not randomized controlled studies.
The levels of evidence are moderate [42]. Second, the
comparison here is between UCBT and UBMT; pe-
ripheral blood stem cell transplantation is not included
in the analysis. Third, duration of follow-up was
mostly short-term. Fourth, there were manuscripts in-
cluded that used registry data. In this type of analysis,
choice of intervention is often governed by a complex
list of unmeasured factors that can potentially affect
outcome, such as the choice of alternative donor and
the time to transplantation. Fifth, acute myeloid leuke-
mia and ALL are different disease entities that require
different chemotherapy regimens for treatment. How-
ever, most comparison studies have included both dis-
eases because of the limitation in the number of
UCBTs given to patients with acute leukemia.CONCLUSION
We conclude that UCBT was associated with less
GVHD, more engraftment failure and TRM, similar
relapse, and shorter survival. At the same time, there
was no difference in LFS and OS in patients with
ALL when studies were pooled. Taken together, these
results suggest that UCBT led to inferior outcomes
than UBMT in patients with acute leukemia. UCBT
could be considered as an alternative stem cell source
for patients with acute leukemia, especially when an
unrelated marrow donor is not available in a timely
fashion. The present report suggests that large samples
and well-designed studies to test these observations are
warranted.ACKNOWLEDGMENTS
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